Longeveron Appoints Nirav S. Jhaveri as Chief Financial Officer

What happened

Longeveron Inc. (Nasdaq: LGVN) announced in an 8-K filing dated Aug. 19, 2026, that it has appointed Nirav S. Jhaveri as Chief Financial Officer, principal financial officer, and principal accounting officer, effective Aug. 17, 2026.

Marie Washburn, who had been serving as CFO, will remain with the company in her prior role of Vice President and Corporate Controller.

The filing describes Mr. Jhaveri's compensation: an initial base salary of $400,000 per year, eligibility for a performance-based annual cash incentive with a target of 45% of base salary, and an equity award of 300,000 restricted stock units vesting quarterly over three years. He also receives standard benefits and severance terms under a letter agreement filed as Exhibit 10.1.

Who is Nirav S. Jhaveri

Mr. Jhaveri, age 48, has over 25 years of biopharma and biotech leadership experience. He most recently served as an independent strategic advisor to early-stage biotech companies.

Previously, he was CFO of Opus Genetics, Inc. (Nasdaq: IRD) from February 2024 to June 2025, Insilico Medicine from 2021 to 2023, and Journey Medical Corporation from 2020 to 2021. He holds a B.A. from the University of Pennsylvania and an MBA from New York University.

The filing states there are no arrangements or understandings with other persons regarding his selection, no family relationships with company directors or officers, and no reportable related-party transactions.

What this means

An 8-K is a current report that public companies must file with the SEC to announce major events, including changes in executive leadership. Item 5.02 covers the departure and appointment of officers.

This is a standard disclosure of a C-suite change. The appointment is effective immediately, and the company is required to report the terms of the officer's compensation.

The restricted stock units (RSUs) are a form of equity compensation: each unit represents a right to receive one share of common stock once vested. Quarterly vesting over three years means the award is designed to retain the executive over the long term.

Longeveron is a clinical-stage biotechnology company focused on cellular therapies for aging-related conditions. It reported annual revenue of approximately $1.2 million for the period ending Dec. 31, 2025.

The stock closed at $0.8449 on the event date, up 2.04% from the prior close. The 8-K does not explain the price move.